Increase in Lymphadenitis Cases after Shift in BCG Vaccine Strain.

• Type of Material: Article
• Authors: Giorgi Kuchukhidze, National Center for Disease Control; Ana Kasradze, National Center for Disease Control; Tamar Dolakidze, National Center for Disease Control; David Baliashvili, National Center for Disease Control; Tsira Merabishvili, National Center for Disease Control; Henry Blumberg, Emory University; Russell Kempker, Emory University
• Language: English
• Date: 2015-09
• Publisher: Centers for Disease Control and Prevention
• Publication Version: Final Published Version
• Copyright Statement: All materials published are in the public domain and can be used without permission.
• Final Published Version (URL): http://dx.doi.org/10.3201/2109.150289
• Title of Journal or Parent Work: Emerging Infectious Diseases
• ISSN: 1080-6040
• Volume: 21
• Issue: 9
• Start Page: 1677
• End Page: 1679
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Public Health

Abstract

Bacillus Calmette-Guérin (BCG) vaccine is one of the most commonly used vaccines for tuberculosis (TB) worldwide (1). The original BCG strain was developed in 1921. Numerous strains have since been developed, and 5 strains, including Danish SSI 1331 (Statens Serum Institute, Copenhagen, Denmark), account for >90% of BCG vaccine used. Each strain has unique characteristics and a different reactogenicity profile (2). The most common severe adverse events related to BCG vaccination are nonsuppurative and suppurative lymphadenitis.